3 who were enrolled in a phase I immunotherapy trial comparing two schedules of immunization of an HIV-1 IIIB-based recombinant gp160 (rgp160) experimental vaccine were evaluated for rgp160-specific antibodies in parotid saliva, genital secretions, and serum. When the study was unblinded, it was determined that five volunteers had received rgp160 on a month 0, 1, 2, 3, 4, and 5 immunization schedule, seven volunteers had received rgp160 on a month 0, 1, 2, and 5 schedule, five had received alum/deoxycholate placebo, and seven had received a licensed hepatitis B virus vaccine. Five volunteers consented to the donation of parotid saliva but not genital secretions. Prior to immunization, parotid saliva specimens were available for 11 of 22 volunteers, seminal plasma (SP) specimens were available for 7 of 22 volunteers, cervicovaginal lavage (CVL) specimens were available for 5 of 22 volunteers, and serum was available for 22 of 22 volunteers. These baseline specimens and specimens collected at 1 and 7 months after the final immunizations were assessed by enzyme-linked immunosorbent assay for immunoglobulin G (IgG) and IgA antibodies specific for HIV-1 LAI rgp160 or HIV-1 MN rgp160. No augmentation in HIV rgp160-specific IgG or IgA antibody production in either parotid saliva or serum specimens of vaccinees compared to that in controls was observed after immunization. There were insufficient numbers of SP or CVL specimens available for statistical comparisons between vaccinees and controls. Overall, anti-LAI rgp160 IgG antibodies were detected in the parotid saliva specimens of 20 of 22 volunteers, the seminal plasma specimens of 11 of 11 volunteers, and the CVL specimens of 6 of 6 volunteers and in 21 of 22 serum specimens. Fewer volunteers expressed anti-LAI rgp160 IgA antibodies in mucosal or serum specimens: 11 of 22 parotid saliva specimens, 3 of 11 SP specimens, 3 of 5 CVL samples, and 12 of 22 sera.
Redfield et al. reported that genetically engineered envelope glycoprotein antigen derived from the human immunodeficiency virus type 1 (HIV-1) gp160 gene when administered to HIV-infected patients by repeated monthly parenteral immunizations boosted both systemic humoral and cellular immune responses to HIV (20) . Although phase I studies have not established the efficacy of vaccine therapy for treating HIVinfected individuals, these studies have shown that in vivo natural host immunity to HIV is responsive to HIV recombinant antigen manipulation. The strategy behind vaccine therapy trials is to affect the clinical course of HIV by boosting the host immune system to suppress viral replication. This approach, called therapeutic vaccination, is an important but largely unproven concept. Straus et al. investigated the effect of a vaccine containing recombinant glycoprotein D of herpes simplex virus type 2 (HSV-2) on the frequency of symptomatic outbreaks in patients with genital herpes (23) . They found that volunteers who received this experimental vaccine had fewer recurrences of genital herpes. The protective effect appeared to be partially mediated by neutralizing antibodies to HSV-2, which was not seen in those who received placebo or in those who had natural genital herpes recurrences. Other protective effects, in the opinion of Straus et al., included the development of circulating T cells responsive to the herpes recombinant vaccine and possibly the induction of cellular or cytokine responsiveness to HSV-2. These results, the first controlled confirmation that a vaccine can modify the course of chronic viral infection in humans, provide hope for the potential use of vaccine for the treatment of chronic, recurring viral diseases.
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In the present study, asymptomatic HIV-1-infected volunteers were enrolled in a blinded, placebo-controlled phase I immunotherapy trial of an HIV-1 IIIB-based recombinant gp160 (rgp160) experimental vaccine. All volunteers were monitored for safety and changes in systemic HIV-specific antibody and lymphoproliferative responses. A subset of 22 of the 55 volunteers enrolled in the trial at Johns Hopkins University consented to be evaluated for changes in HIV-specific antibody responses detectable in parotid saliva and genital secretions. The results of this mucosal substudy are the subject of this paper.
MATERIALS AND METHODS
Study population. Volunteers were healthy, asymptomatic, HIV-1-infected adults of both sexes. At study entry, all volunteers had a normal history, physical examination, and blood count; no serological evidence of chronic hepatitis B infection (hepatitis B surface antigen negative); and a mean morning CD4 cell count of Ͼ600 cells/mm 3 . None had used any antiviral agents in the 6 months prior to enrollment in the trial. By self-report, the probable mode of HIV-1 infection for 12 volunteers was homosexual transmission, that for 5 volunteers was heterosexual transmission, and that for the remaining 5 subjects was intravenous drug use. Written informed consent for participation in the trial as well as for collection of the mucosal specimens was obtained from all 22 volunteers who participated in the study. The trial and the mucosal substudy were approved by the Joint Committee of Clinical Investigations of the Johns Hopkins University Medical Institutions.
Vaccine. The experimental vaccine is a recombinant envelope glycoprotein (rgp160) based on HIV-1 IIIB which is produced by Immuno AG, Vienna, Austria. The rgp160 is produced using a recombinant vaccinia virus HIV-1 gp160/bacteriophage T7 hybrid system expressed in Vero cells as previously described (5) . The rgp160 was administered in 50-g doses adjuvanted in aluminum hydroxide (alum, 0.05%) with deoxycholate (DOC, 0.06%) and thimerosal preservative (0.01%). The placebo was the alum/DOC adjuvant vehicle. A licensed, recombinant yeast-derived hepatitis B virus vaccine (Energix; Smith, Kline, and French) was used as a viral vaccine control.
Design of vaccine trial and immunization schedule. The vaccine study was a placebo-controlled, double-blind phase I trial which compared two schedules of immunization. It was conducted by the National Institute of Allergy and Infectious Diseases-sponsored AIDS Vaccine Evaluation Group. Volunteers were randomly assigned to one of four trial arms: (i) 50-g doses of rgp160 on a month 0, 1, 2, 3, 4, and 5 immunization schedule; (ii) 50-g doses of rgp160 on a month 0, 1, 2, and 5 immunization schedule with placebo given at months 3 and 4 to maintain blinding; (iii) the alum/DOC placebo vehicle given on the month 0, 1, 2, 3, 4, and 5 schedule; or (iv) hepatitis B virus vaccine given on the month 0, 1, 2, and 5 schedule with placebo given at months 3 and 4 to maintain blinding. All products were administered by intramuscular injection into the deltoid muscle. Volunteers and investigators were blinded with respect to the trial arm to which the volunteer was randomized. The volunteers were monitored for safety prior to initial immunization and at periodic intervals during the trial by clinical observation following immunization and by measurement of hematologic parameters, including CD4 cell count, renal function, and hepatic function. A data safety and monitoring board consisting of external reviewers periodically monitored the findings of the study to ensure the safety of the volunteers. A preliminary report of the trial was presented elsewhere (22) .
Collection and storage of volunteer specimens. Parotid saliva, cervicovaginal lavage (CVL), and semen specimens were collected from the HIV-1-infected volunteers at entry into the trial, 6 months after initial immunization, and 6 months following final immunization. Both volunteers and investigators were blinded as to which arm of the trial the volunteer was enrolled in. Parotid saliva was collected with a collection device (saliva collection cup; Stone Machine Co., Coulton, Calif.) affixed to the buccal mucosa overlying the orifice of Stenson's duct. Production of saliva was stimulated by a sour candy. CVL specimens were collected in midcycle of the women's menstrual cycle by flushing the vaginal vault with 10 ml of sterile nonbacteriostatic saline and then aspirating the fluid with a syringe. Semen samples were self-collected by the male volunteers through manual stimulation and delivered to the laboratory for processing within 1 hour. Seminal plasma was obtained by diluting the semen with an equal volume of phosphate-buffered saline (PBS) and centrifuging it at 1,200 ϫ g for 10 min to remove cellular debris. Serum was also obtained from all the volunteers at the same time points that mucosal specimens were collected by conventional venipuncture. The mucosal and serum specimens were stored frozen at Ϫ20°C until tested.
Calculation of total IgG and IgA concentrations. Total immunoglobulin G (IgG) and IgA in parotid saliva, CVL, and seminal plasma were determined by an enzyme-linked immunosorbent assay (ELISA) method. Briefly, a microtiter ELISA plate was coated with either goat anti-human IgG or goat anti-human IgA (Sigma Chemical Co., St. Louis, Mo.) in PBS. The plate was held overnight at 4°C and washed in PBS-0.05% Tween 20. Purified IgG and IgA standards (Accurate Chemical & Scientific Corp., Westbury, N.Y.) were tested at half-log dilutions ranging from 0.10 to 0.0033 mg/ml for IgG and from 0.033 to 0.001 mg/ml for IgA. Study samples were tested at fourfold dilutions starting at 1:160 for IgG and 1:40 for IgA. IgG and IgA antibodies were detected using horseradish peroxidase-conjugated goat antibody specific for human gamma chain or human alpha chain (Zymed Laboratories, Inc., South San Francisco, Calif.) and ABTS [2,2Ј-azinobis(3-ethylbenzthiazolinesulfonic acid)] substrate (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, Md.). Optical density (OD) was measured using a kinetic microplate reader (Molecular Devices, Menlo Park, Calif.). Total IgG and IgA concentrations were derived by interpolation from the standard curve.
Measurement of anti-HIV-1 gp160 IgG and IgA antibodies. To measure the IgA and IgG gp160-specific antibody responses in the mucosal specimens and serum, an ELISA specific for HIV-1 gp160 was performed as previously described with minor modifications (11, 26) . Highly purified preparations of baculovirus/insect cell-expressed HIV-1 LAI rgp160 and a HIV-1 MN rgp160 (MicroGeneSys, Meriden, Conn.) were used as coating antigens at 1-mg/ml concentrations in the ELISAs. For IgG determinations, parotid saliva, CVL, and semen specimens were tested at 0.5 mg of total IgG per ml. For IgA determinations, parotid saliva was tested at 2 mg of total IgA per ml, whereas CVL and semen were tested at 0.5 mg of total IgA per ml. Serum was tested at a 1:10,000 dilution for IgG and a 1:400 dilution for IgA, as these dilutions had been determined to reliably give on-scale readings in the ELISAs. For IgA determinations in specimens from mucosal sites, the specimens were treated with a solution of 2% goat anti-human IgG antibody (Sigma) in order to precipitate IgG, which might competively block binding of IgA. Cutoff ODs for ELISA For each parotid saliva and semen specimen, a regression analysis of the OD of the specimens at 6 or 12 months post-initial immunization was performed on the preimmunization OD value and trial arm (i.e., HIV rgp160, hepatitis B, or adjuvant alone). Data were analyzed with an F-test with 1 df. The change in OD readings from baseline to follow-up was compared for vaccine and placebo recipients by using a general linear model in which follow-up values were controlled for baseline values. The mean change in OD readings from baseline to follow-up was also tested using a t test. For inclusion in the t test, the OD reading had to be positive either at baseline, at the postimmunization time point, or at both time points.
RESULTS
Of the 22 volunteers who participated in the mucosal study, 15 were male and 7 were female. Thirteen described themselves as non-Hispanic Caucasians, and the rest described themselves as non-Hispanic African-Americans. The mean age of the volunteers at entry was 35 years, and they ranged in age from 28 to 44 years. The mean entry morning CD4 cell count for the volunteers was 712 cells/mm 3 , with individual values ranging from 480 to 1,263 cells/mm 3 . As shown in Table 1 , when the study was unblinded, it was determined that five volunteers had been in the trial arm receiving rgp160 on the month 0, 1, 2, 3, 4, and 5 immunization schedule; seven volunteers had been in the trial arm receiving rgp160 on the month 0, 1, 2, and 5 immunization schedule; five volunteers had received the alum/DOC placebo; and the remaining seven volunteers had received hepatitis B virus vaccine. Five of the volunteers (volunteers V2, V8, and V11 in the vaccine arms and V13 and V18 in the control arms) consented to the donation of parotid saliva but not of genital secretions. Baseline parotid saliva specimens were available for 11 of 22 volunteers, seminal plasma was available for 7 of 22 volunteers, and CVL specimens were available for 5 of 22 volunteers. Serum specimens were available for the baseline (month 0), month 6, and month 12 time points for all volunteers.
As only one rgp160 recipient (V6) and one control (V14) had both a baseline and a month 6 CVL specimen collected, no statistical analysis of the CVL data for vaccine recipients versus controls was done. Only one rgp160 recipient on each immunization schedule (V3 and V9) had a semen specimen collected prior to immunization and 6 months into the trial. Three control volunteers (V16, V19, and V20) had both baseline and month 6 semen specimens available. By inspection, there was no discernible effect of immunization on antibody responses in the seminal plasma specimens of the two vaccinees. Indeed, vaccinee V3 was less reactive with the ELISA panel at 6 months than at baseline, as were two of the controls, V16 and V19. All three were anti-HIV-1 LAI rgp160 IgA positive in baseline specimens, whereas all were negative for this antigen and Ig subclass at 6 months.
Seven rgp160 recipients (four on the month 0, 1, 2, 3, 4, and The four volunteers who received rgp160 in months 1, 2, 3, 4, and 5 were combined with the three volunteers who received rgp160 on the other schedule as a single vaccinee group. Likewise, the two recipients of the alum/DOC placebo were combined with the three hepatitis B virus vaccine recipients as a single control group.
c The ⌬OD is calculated by subtracting the OD reading at baseline for each volunteer with at least one positive result for the particular antigen/Ig combination at either baseline or the postimmunization timepoint in the comparison from the OD reading at 6 or 12 months for the volunteer. (Tables 1 and 2 ). As shown in Table 2 , no augmentation in HIV rgp160-specific antibody production in the parotid saliva of rgp160 recipients compared to that in controls, who were positive for the particular antigen/Ig combination in the ELISA at baseline, was observed after immunization. In addition, among those volunteers who were negative at baseline but positive at the month 6 or 12 for a particular antigen/Ig combination, there was no difference between rgp160 recipients and controls in the numbers of new positive responses. There were also no statistically significant increases in rgp160 antibody production in serum specimens in vaccinees compared to controls following immunization (see baseline/month 6 comparison in Table 2 ).
Changes from baseline to month 6 or 12 in serum and in parotid saliva were not statistically correlated.
The overall findings of HIV-1 LAI or MN rgp160-specific antibody responses in the parotid saliva, genital secretions, and sera of the volunteers are presented in Table 3 . In parotid saliva specimens of the volunteers for whom preimmunization specimens were available, IgA was the predominant immunoglobulin present. The mean total IgA in these parotid saliva specimens was 15.36 Ϯ 6.55 (standard deviation) g/ml, and total IgG was 2.07 Ϯ 2.27 g/ml. In contrast, the HIV rgp160-specific response in parotid saliva was predominantly in the IgG compartment. In the semen and CLV specimens, IgG was the predominant immunoglobulin present. In preimmunization specimens, mean total IgG in CVL specimens was 10.14 Ϯ 3.77 g/ml, and mean total IgA was 2.8 Ϯ 1.77 g/ml. In baseline seminal plasma specimens, mean total IgG was 13.88 Ϯ 9.97 g/ml, and mean total IgA was 1.33 Ϯ 0.65 g/ml.
One hundred percent of volunteers tested for anti-HIV-1 LAI rgp160 IgG antibodies in genital secretions were positive at at least one time point. Few seminal plasma specimens also contained IgA antibodies to either LAI or MN rgp160, whereas, 60 to 80% of CVL specimens did.
DISCUSSION
In two different phase I clinical trials with non-HIV-1-infected volunteers, the same 50-g dose of the candidate HIV-1 IIIB rgp160 vaccine, administered on accelerated schedules of immunization the same or similar to those employed in the trial described herein (at months 0, 1, 2, and 5 and at months 0, 1, 2, 3, and 4) or on a more conventional month 0, 1, 6, and 12 schedule, induced HIV-1 IIIB or LAI rgp160 binding antibodies in almost all the volunteers 2 to 4 weeks after the final immunization (8, 13) . In the latter trial, whole saliva of six of the rgp160 recipients was also tested for the presence of antirgp160 (IIIB) IgG and IgA antibodies after the month 12 immunization (12). All six volunteers had detectable antirgp160 IgG antibody responses, and three of them had a transient anti-rgp160 IgA response. Thus, it was unexpected in the present study that no augmentation or induction of HIV-1 rgp160 binding antibodies in at least the sera of the HIV-1-infected subjects in the rgp160 arms of the trial was observed 1 month after the final immunizations.
The lack of augmentation or induction of HIV rgp160-specific binding antibodies in HIV-infected volunteers who are already producing anti-HIV antibodies may be a dose effect. In non-HIV-1-infected volunteers, a 200-g dose of the HIV-1 IIIB rgp160 candidate vaccine tested in this study appears to be more immunogenic (8) . In immunotherapy trials with another candidate envelope subunit product, a baculovirus-expressed HIV-1 LAI rgp160, dose-ranging studies indicated that increases in antibody levels or induction of antibodies in serum to new epitopes on rgp160 usually or only developed in recipients receiving higher doses of the rgp160 vaccine (20, 24) . For example, 78% of volunteers receiving a 1,280-g dose of the LAI rgp160 developed new antibodies (24) . In contrast to what is seen with the antibody response, all the candidate HIV envelope subunit vaccines employed thus far in immunotherapy trials, including the Immuno AG HIV-1 IIIB rgp160, have induced new HIV-envelope-specific lymphoproliferative responses in some of the volunteers, even at the lowest doses utilized (14-16, 20, 22, 24) .
Immunoglobulin present in mucosal secretions is of one of two origins: locally produced immunoglobulin, most usually secretory IgA, which is considered to be a true mucosal response, or immunoglobulin transuded from the systemic circulation, usually of the IgG class (17) . Either of these immunological responses could prove to be of benefit to the host. In parotid saliva, the immunoglobulin is almost completely local in origin. Genital secretions usually contain both transuded and local immunoglobulins (17, 18) . To date, the immunological and virologic effects of these therapeutic products have been measured primarily in serum specimens, and there are few data on the ability of vaccine therapy to stimulate antibody production at mucosal surfaces.
A study by Gorse et al., performed with non-HIV-infected volunteers who received the same candidate HIV vaccine as in our study (Immuno AG), revealed the presence of anti-envelope glycoprotein IgG and IgA antibodies in whole saliva following immunization with a recombinant rgp160 vaccine (12) . A study by Burnett et al. evaluated the ability of HIV-seropositive-individual IgA immune responses in serum to neutralize HIV in vitro (10). They were able to demonstrate HIV-neutralizing activity in the IgG-depleted sera and affinity-purified IgA1 serum fractions of three HIV-infected individuals who mounted a serum IgA response against HIV MN envelope antigen. Mucosal specimens were not tested in this study.
In addition to the report by Gorse et al. (12) describing the HIV-1 rgp160-specific response observed in whole saliva of non-HIV-1-infected volunteers immunized with the Immuno AG HIV-1 IIIB rgp160 experimental vaccine, a few reports of the anti-HIV antibody response detected in whole or parotid saliva of non-HIV-1-infected volunteers parenterally immunized with another candidate AIDS vaccine, a baculovirusexpressed HIV-1 LAI recombinant rgp160, have been published (1, 11, 25) . In one study, envelope-specific antibodies of the IgG class were observed in whole saliva but not parotid saliva of some volunteers immunized with 640-or 1,280-g doses of rgp160 (25) . In a second study, which used an ELISA similar to that used for the present study, volunteers receiving 160-or 640-g doses of rgp160 developed rgp160-specific IgG antibody in nasal washes (four of eight volunteers tested) but not in parotid saliva (11) .
Studies of HIV-1-specific antibody responses in parotid saliva and genital secretions of HIV-1-infected subjects also have been published (6, 7, 11, 12, 19, 27) . In the present study, 91% of the volunteers had detectable anti-rgp160 IgG antibodies in parotid saliva, but only 9 or 50% had anti-MN rgp160 IgA or anti-LAI rgp160 IgA antibodies, respectively. The predominant HIV-1 gp160-specific response observed in parotid saliva in other studies was also of the IgG class, suggesting that most of the HIV-specific antibody in parotid saliva is transuded rather than locally produced (3, 4, 11) . Using radioimmuno-precipitation assays that employ whole-virus lysate and developing reagents for both IgG and IgA antibodies or only IgA antibodies, Archibald et al. observed that the parotid saliva samples of five or five volunteers positive for HIV-specific antibodies in the IgG/IgA assay were also positive in the IgAonly assay (3) . Eleven (38%) of 29 women who had anti-rgp160 IgG antibodies in parotid saliva also had detectable antirgp160 IgA antibodies in ELISAs (4) . Five of 18 HIV-positive subjects had HIV-1 LAI rgp160-specific IgG antibodies in parotid saliva specimens in an ELISA similar to that used in the current study, whereas, only 1 of 8 (5.5%) of these volunteers was producing anti-rgp160 IgA antibodies (11) .
Several studies of the IgG and IgA HIV-specific antibody responses in female genital secretions have been done, and a variety of assays have been used. With an oligomeric rgp160-based ELISA, 37 of 37 (100%) of women had anti-rgp160 IgG antibodies in CVL specimens and 19 of 37 (51%) had antirgp160 IgA antibodies (4) . With a whole-virus-lysate radio immunoprecipitation assay, seven of seven cervical secretions of HIV-positive women contained HIV-specific IgG antibodies and five of seven (71%) also contained HIV-specific IgA antibodies (3). When commercial HIV-1 Western blots (immunoblots) were used, 28 and 19 of 30 HIV-1 seropositive women had anti-rgp160 IgG and anti-rgp160 IgA antibodies, respectively, present in CVL specimens (6) . In anti-HIV dot blot assays, the vaginal secretions of 24 HIV-positive women all contained anti-rgp160 IgG antibodies, and 42% also contained anti-rgp160 IgA antibodies (19) . These findings are quite consistent with our observations that in 100% (six of six) of the CVL specimens, IgG antibodies reactive with both HIV-1 LAI and MN rgp160 were detectable and that three of five volunteers also expressed anti-LAI rgp160 IgA antibodies and four of five volunteers expressed anti-MN rgp160 IgA antibodies.
According to commercial HIV Western blot, 11 of 11 HIVpositive African men expressed anti-rgp160 IgG antibodies in their seminal plasma, and 8 of the 11 also were producing anti-rgp160 IgA antibodies (7) . In a second study, in the United States, that employed a commercial whole-HIV-lysate ELISA, 28 of 28 HIV-1-seropositive men's seminal plasma samples contained HIV-specific IgG antibodies (27) . When the seminal plasma samples of 13 of these men were assessed by Western blot, all expressed anti-rgp160 IgG antibodies, but none expressed anti-rgp160 IgA antibodies. Our study also detected anti-LAI rgp160 IgG antibodies in 100% (11 of 11) of volunteer seminal plasma specimens. Three of 11 (37%) and 1 of 11 (9%) of the men also had anti-LAI rgp160 IgA and anti-MN rgp160 IgA antibodies, respectively. In this study, following immunization with a recombinant gp160 IIIB vaccine, no statistically significant increases in HIV-specific antibody to IgG or IgA classes were detected in the serum or mucosal specimens tested.
Stimulation of HIV-specific antibody in individuals already infected with HIV could theoretically decrease the infectiousness of that individual and decrease the risk of the sexual spread of HIV, either by stimulation of HIV-specific IgA antibody at mucosal surfaces or by transudation of HIV-specific IgG from the systemic to the mucosal compartment. These antibodies could play a role in neutralization of HIV on these mucosal surfaces by blocking viral attachment, blocking entry into susceptible cells of the mucosa, or both. The efficacy of the herpes simplex recombinant vaccine tested by Straus et al. was not fully explained by serum neutralization responses; in their study, mucosal specimens were not collected to test the role of virus-specific antibody responses generated on mucous membrane surfaces (23) . Our study tested the hypothesis that individuals primed by HIV infection could have mucosal antibody responses boosted by vaccine immunotherapy. In our trial, following administration of the Immuno AG rgp160 envelope glycoprotein HIV vaccine, we were unable to demonstrate such an effect in mucosal and serum specimens. In the Redfield immunotherapy trial, which utilized the MicroGeneSys rgp160 IIIB HIV-1 vaccine, increases in serum antibody responses were detected following vaccination (20) . The assays performed in the Redfield laboratories measured antibody to whole HIV proteins, utilizing both recombinant viral gene products (gp160, p66, p24) and whole viral lysate of prototype HIV strain MN by dot blotting and Western blot techniques. The most significant findings of their study involved finding antibody responses to specific envelope epitopes (49, 88, 106, 241, 254, 300, 308, 342, 422, 448, 582, and 735) which were not measured in our study. An additional analysis of specimens from the Redfield study (9) , which utilizes a technique of spectrotypic analysis done by isoelectric focusing and reverse blotting, detected differences in sera of HIV vaccine but not placebo recipients. Such an analysis was not performed in the current study. Our failure to find differences in vaccinated individuals may indicate a lack of sensitivity in our assay methods rather than a failure of the vaccine to generate a humoral immune response. Future analyses of specimens from our study, both serum and mucosal, should include techniques similar to those described above. Of note, volunteers in this trial who received hepatitis B vaccine developed protective antibody levels as measured by hepatitis B surface antibody (data not shown), suggesting that these volunteers had relatively intact immune systems and were capable of responding to vaccines. While conventional wisdom would not anticipate that parenteral vaccines would generate mucosal antibody responses, most experience to date has been with utilizing vaccines in a prophylactic role. It is not unreasonable to anticipate that individuals primed by natural HIV infection could have a boosting of this response on mucosal surfaces following recombinant antigen administration and presentation to the immune system.
The final tests of a therapeutic HIV vaccine will be whether augmented immune responses translate into decreased viral load in systemic and viral compartments and whether such changes translate into clinical benefit. It will be important, in future studies, to evaluate if augmented antibody responses on mucosal surfaces can decrease viral shedding, since viral load is likely a major determinant of the infectivity of HIV.
